MorphoSys AG has expanded its strategic alliance with Novartis to include new technologies aimed at accelerating the discovery of new therapeutic antibodies and to increase the overall productivity of the collaboration. Financial details were not disclosed.   The companies will apply a suite of new technologies available to MorphoSys, including Ylanthia and Slonomics, to make therapeutic antibodies. The companies will also cross-license future technology improvements for their mutual benefit. No...